- Home
- ANAB vs TIGR Comparison
ANAB vs TIGR Comparison
Compare ANAB & TIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | TIGR |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANAB | TIGR |
|---|---|---|
| Price | $60.37 | $5.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $71.67 | $14.20 |
| AVG Volume (30 Days) | 586.1K | ★ 2.3M |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $52.14 | $5.95 |
| P/E Ratio | ★ N/A | $9.77 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $5.81 |
| 52 Week High | $73.30 | $13.55 |
Technical Indicators
Market Signals| Indicator | ANAB | TIGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 38.07 |
| Support Level | $53.46 | N/A |
| Resistance Level | $67.69 | $7.00 |
| Average True Range (ATR) | 4.38 | 0.26 |
| MACD | -0.93 | -0.07 |
| Stochastic Oscillator | 19.86 | 13.77 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.